FEMASYS INC (FEMY): Nasdaq/NYSE listing notice — Femasys receives Nasdaq minimum bid price non-compliance notice; 180-day cure period

FEMASYS INC

Nasdaq notified Femasys on July 16, 2025, of non-compliance with $1.00 minimum bid price for 30 consecutive business days.
Company has until January 12, 2026, to regain compliance by closing at $1.00+ for 10 consecutive business days.
If not cured, Femasys may qualify for an additional 180-day period if it meets other initial listing standards.
Management may consider a reverse stock split to cure the deficiency; no immediate impact on trading.
Failure to regain compliance could lead to delisting; the company can appeal any delisting determination.

item 3.01

Key facts

Extracted from this filing and checked against the source text.

Listing & Compliance Notices SEC 8-K Item 3.01 confidence 0.99

FEMASYS INC received a nasdaq deficiency notice notice regarding minimum bid price (rules 5550(a)(2)).

Exchange: nasdaq
Notice: deficiency notice
Deficiency: minimum bid price
Rules: 5550(a)(2)

Exact text from the filing

July 16, 2025, Femasys Inc. (the “Company”) received a notice from The Nasdaq Stock Market (“Nasdaq”) that the Company is not in compliance with Nasdaq’s Listing Rule 5550(a)(2), as the minimum bid price of the Company’s common stock has been below $1.00 per share for 30 consecutive business days (the “Minimum Bid Price Requirement”). The notification of noncompliance has no immediate effect on the listing or trading of the Company’s common stock on The Nasdaq Capital Market. The Company has 180 calendar days, or until January 12, 2026, to regain compliance with the Minimum Bid Price Require

View on SEC.gov

Browse all listing & compliance notices →

FEMASYS INC filing history →

Source: SEC EDGAR

accession 0001140361-25-026431

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.